Deals channel feed – Endpoints News

Deals channel feed

Biogen hands Denali $1B-plus in cash, $1B-plus in milestones to partner on late-stage Parkinson’s drug

5 years ago

Stem cell player ViaCyte expands collaboration with Gore to develop subcutaneous diabetes treatment

5 years ago

Merck scoops up a PhII J&J discard in a bargain-basement deal. And this time they’re shooting at NASH

5 years ago

AstraZeneca throws Redx a lifeline — in exchange for a preclinical fibrosis drug — with a promise of $17M in quick cash plus milestones

5 years ago

Sanofi and GSK say they're near a vaccine deal with EU hours after finalizing Warp Speed contract

5 years ago

Novartis turns to Sangamo with a $795M-plus deal aimed at using zinc finger tech for the neuro pipeline

5 years ago

F-star's Eliot Forster maps a shortcut to Wall Street, bagging more cash to fuel oncology pipeline work

5 years ago

Lexicon bids farewell to top seller Xermelo in reorganization toward R&D pipeline

5 years ago

The lead drug in Alexion’s $930M buyout deal last fall just flopped — adding injury to analysts’ M&A insults

5 years ago

Roche/Genentech doubles down on tau, fronting $120M cash to ally on a 2-pronged strategy to fight Alzheimer’s

5 years ago

AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’

5 years ago

Fast follow: EQRx engineers $410M-plus worth of deals to CDK4/6, EGFR drugs

5 years ago

Juno/WuXi's cell therapy venture buys out solid tumor player in China, gaining a discovery engine and portending more M&A to come

5 years ago

Leo Pharma offloads a psoriasis asset as their Dupixent rival heads to the FDA

5 years ago

Gilead lines up a $1.55B biotech buyout deal as CEO Dan O’Day invests in his latest cancer blockbuster dream

5 years ago

Roche partners on a slate of Jnana's immunology, neurology targets, rewarding its faith in the SLC transporter class

5 years ago

BeiGene expands pipeline and hops on board a quest to cure hep B, inking a $540M deal with a fellow upstart biotech

5 years ago

GSK injects $293M cash into CureVac, forging a deal to develop new mRNA vaccines and antibodies

5 years ago

Suggested by Bloomberg, blessed by analysts, could an M&A match with a certain MS player be far off for blockbuster-hungry Sanofi?

5 years ago

Gilead's ex-R&D chief Bischofberger heads back to the biotech giant to pick up a pair of late-stage drugs that had been put aside

5 years ago

Sanofi keeps foot on the gas, agreeing to five-year collaboration with MD Anderson

5 years ago

Diagnostic champ Roche buys its way into the RET title fight with Eli Lilly, paying $775M in cash to Blueprint

5 years ago

Massachusetts biotech Revitope scores first collaboration thanks to dual-engaging T cell platform

5 years ago

Two years after a ‘positive’ result tanked their stock, Ovid's Jeremy Levin wins a partner for the PhIII journey

5 years ago

First page Previous page 89 90 919293 94 95 Next page Last page